The Cancer Journal最新文献_第4页

Intratumoral Approaches for the Treatment of Melanoma 瘤内方法治疗黑色素瘤

The Cancer Journal Pub Date : 2017-01-01 DOI: 10.1097/PPO.0000000000000234

P. Bommareddy, A. Silk, H. Kaufman

{"title":"Intratumoral Approaches for the Treatment of Melanoma","authors":"P. Bommareddy, A. Silk, H. Kaufman","doi":"10.1097/PPO.0000000000000234","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000234","url":null,"abstract":"Abstract There have been significant advances in the immunotherapy of melanoma over the last decade. The tumor microenvironment is now known to promote an immune-suppressive milieu that can block effective immune-mediated tumor rejection. Several novel strategies designed to overcome local immunosuppression hold promise for treatment of melanoma and other cancers. These approaches include oncolytic viruses, plasmid DNA delivery, Toll-like receptor agonists, inflammatory dyes, cytokines, checkpoint inhibitors, immunomodulatory agents, and host and pathogenic cell-based vectors. In addition, there are several novel methods for local drug delivery, including direct injection, image-guided, electroporation, and nanodelivery techniques under study. The approval of talimogene laherparepvec (Imlygic), an attenuated, recombinant oncolytic herpesvirus, for melanoma treatment is the first intratumoral agent to receive regulatory approval for the treatment of patients with melanoma. This review will focus on the rationale for intratumoral treatment in melanoma, describe the clinical and safety data for some of the agents in clinical development, and provide a perspective for future clinical investigation with intratumoral approaches. Melanoma has been a paradigm tumor for progress in targeted therapy and immunotherapy and will likely also be the tumor to establish the therapeutic role of intratumoral treatment for cancer.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":"42 1","pages":"40–47"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90274020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 46

Novel Targeted Therapies for Metastatic Melanoma 转移性黑色素瘤的新靶向治疗

The Cancer Journal Pub Date : 2017-01-01 DOI: 10.1097/PPO.0000000000000242

W. Iams, J. Sosman, S. Chandra

{"title":"Novel Targeted Therapies for Metastatic Melanoma","authors":"W. Iams, J. Sosman, S. Chandra","doi":"10.1097/PPO.0000000000000242","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000242","url":null,"abstract":"Abstract Oncogene-targeted therapy is a major component of precision oncology, and although patients with metastatic melanoma have experienced improved outcomes with this strategy, there are a number of potential therapeutic targets currently under study that may further increase the drug armamentarium for this patient population. In this review, we discuss the landscape of targeted therapies for patients with advanced melanoma, focusing on oncogene mutation-specific targets. In patients with typical BRAF V600–mutant melanoma, combination BRAF and MEK inhibition has surpassed outcomes compared with monotherapy with BRAF or MEK inhibition alone, and current strategies seek to address inevitable resistance mechanisms. For patients with NRAS-mutant melanoma, MEK inhibitor monotherapy and combined MEK and CDK4/6 inhibition are burgeoning strategies; for patients with KIT-mutant melanoma, tyrosine kinase inhibition is being leveraged, and for NF-1–mutant melanoma, mTOR and MEK inhibition is being actively evaluated. In patients with atypical, non–V600 BRAF–mutant melanoma, MEK inhibitor monotherapy is the potential novel targeted approach on the horizon. For advanced uveal melanoma, novel targets such as IMCgp100 and glembatumumab have shown activity in early studies. We review additional strategies that remain in the preclinical and early clinical pipeline, so there is much hope for the future of targeted agents for distinct molecular cohorts of patients with advanced melanoma.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":"29 1","pages":"54–58"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86750997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 26

Advances in Interventional Oncology: Lung Cancer 介入肿瘤学进展:肺癌

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000229

P. Dempsey, C. Ridge, S. Solomon

引用次数: 7

Palliative Interventional Oncology 姑息性介入肿瘤学

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000230

A. Fairchild, W. Rilling

引用次数: 4

Increasing Role of Image-Guided Ablation in the Treatment of Musculoskeletal Tumors 影像引导消融在肌肉骨骼肿瘤治疗中的作用日益增强

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000233

A. Kurup, M. Callstrom

{"title":"Increasing Role of Image-Guided Ablation in the Treatment of Musculoskeletal Tumors","authors":"A. Kurup, M. Callstrom","doi":"10.1097/PPO.0000000000000233","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000233","url":null,"abstract":"AbstractIn the last decade, percutaneous treatment of musculoskeletal (MSK) tumors has become more established in routine clinical care while also undergoing a number of advancements. Ablative techniques to palliate painful skeletal metastases have gained wide acceptance, while goals for ablation have evolved to include local control of oligometastases and desmoid tumors. Bone consolidation or augmentation is now frequently used in conjunction with or instead of ablation of skeletal tumors to stabilize pathologic fractures or prevent further morbidity that could result from fractures caused by tumor progression. These procedures have traditionally been performed with cement injection, although additional percutaneous consolidation or stabilization devices have been developed. Techniques to monitor the ablation zone and adjacent structures intraprocedurally are now applied to increase the number of tumors amenable to treatment. These include methods to depict, displace, or monitor critical structures adjacent to targeted MSK tumors. Finally, the role of ablation in the comprehensive care of patients with MSK tumors continues to change with the evolving triage of patients between radiation therapy, surgical resection and stabilization, and percutaneous ablative and consolidative management.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":"134 1","pages":"401–410"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74274420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

New Developments in Interventional Oncology: Liver Metastases From Colorectal Cancer 介入肿瘤学的新进展:结直肠癌肝转移

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000226

J. Kallini, A. Gabr, N. Abouchaleh, R. Ali, A. Riaz, R. Lewandowski, R. Salem

引用次数: 11

Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation 肝细胞癌介入肿瘤学:通过创新取得进展

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000227

L. Mu, J. Chapiro, J. Stringam, J. Geschwind

{"title":"Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation","authors":"L. Mu, J. Chapiro, J. Stringam, J. Geschwind","doi":"10.1097/PPO.0000000000000227","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000227","url":null,"abstract":"AbstractThe clinical management of hepatocellular carcinoma has evolved greatly in the last decade mostly through recent technical innovations. In particular, the application of cutting-edge image guidance has led to minimally invasive solutions for complex clinical problems and rapid advances in the field of interventional oncology. Many image-guided therapies, such as transarterial chemoembolization and radiofrequency ablation, have meanwhile been fully integrated into interdisciplinary clinical practice, whereas others are currently being investigated. This review summarizes and evaluates the most relevant completed and ongoing clinical trials, provides a synopsis of recent innovations in the field of intraprocedural imaging and tumor response assessment, and offers an outlook on new technologies, such as radiopaque embolic materials. In addition, combination therapies consisting of locoregional therapies and systemic molecular targeted agents (e.g., sorafenib) remain of major interest to the field and are also discussed. Finally, we address the many substantial advances in immune response pathways that have been related to the systemic effects of locoregional therapies. Knowledge of these new developments is crucial as they continue to shape the future of cancer treatment, further establishing interventional oncology along with surgical, medical, and radiation oncology as the fourth pillar of cancer care.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":"14 1","pages":"365–372"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86558884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Liver Metastases From Noncolorectal Malignancies (Neuroendocrine Tumor, Sarcoma, Melanoma, Breast) 非结直肠恶性肿瘤(神经内分泌肿瘤、肉瘤、黑色素瘤、乳腺)肝转移

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000232

E. Alexander, M. Soulen

引用次数: 6

Era of a Single Population-Based Payment to a Cancer Center: Delivering the Value of Interventional Oncology in Accountable Care Organizations 以人群为基础向癌症中心支付单一费用的时代:在负责任的护理组织中提供介入肿瘤学的价值

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000231

J. Jia, R. Lencioni, H. Forman, H. S. Kim

引用次数: 1

Kidney Cancer 肾癌

The Cancer Journal Pub Date : 2016-11-01 DOI: 10.1097/PPO.0000000000000225

R. Motzer, N. Agarwal, C. Beard, S. Bhayani, G. Bolger, M. Carducci, Sam S. Chang, T. Choueiri, S. Hancock, G. Hudes, E. Jonasch, D. Josephson, T. Kuzel, E. Levine, D. Lin, K. Margolin, M. Michaelson, T. Olencki, R. Pili, T. W. Ratliff, B. Redman, C. Robertson, C. Ryan, J. Sheinfeld, P. Spiess, Jue Wang, R. Wilder

{"title":"Kidney Cancer","authors":"R. Motzer, N. Agarwal, C. Beard, S. Bhayani, G. Bolger, M. Carducci, Sam S. Chang, T. Choueiri, S. Hancock, G. Hudes, E. Jonasch, D. Josephson, T. Kuzel, E. Levine, D. Lin, K. Margolin, M. Michaelson, T. Olencki, R. Pili, T. W. Ratliff, B. Redman, C. Robertson, C. Ryan, J. Sheinfeld, P. Spiess, Jue Wang, R. Wilder","doi":"10.1097/PPO.0000000000000225","DOIUrl":"https://doi.org/10.1097/PPO.0000000000000225","url":null,"abstract":"AbstractThe number of new cases of renal cell carcinoma has been steadily increasing since the 1960s, reaching 62,000 and 89,000 annually in the United States and Europe, respectively, in 2016. The current standard of care for early-stage disease is nephron-sparing surgery, which has a demonstrated long-term disease-free survival and an acceptable safety profile. Technical developments (thin, powerful probes and real-time image guidance systems) have allowed image-guided percutaneous ablation to become a viable option for stage I renal cell carcinoma. Because of the widespread use of cross-sectional imaging, most renal tumors (75%) are indeed detected incidentally at stage I (75%). As a result, ablation is a potentially curable intervention and one that could mitigate surgical risks. All 3 ablative modalities (radiofrequency ablation, microwave ablation, and cryoablation) have been extensively applied. The utilization of ablation was initially hampered by the lack of prospective, long-term oncologic data. As a result, ablation was reserved for specific subgroups of patients, for example, patients with solitary kidney, chronic kidney disease, or bilateral disease; poor surgical candidates; or patients with syndromes that predispose them to renal cell cancer. Recently, however, studies on percutaneous ablation for early-stage renal cancer have yielded prospective, long-term oncologic data, affirming the earlier, lower-level-evidence studies. The reported efficacy of ablation for stage I renal cancer (especially cryoablation) appears to rival that of the accepted standard of care (nephron-sparing surgery), whereas its safety profile is a decided advantage. In conclusion, image-guided percutaneous ablation should be considered a viable, curative option for stage IA renal cell carcinoma.","PeriodicalId":22430,"journal":{"name":"The Cancer Journal","volume":"74 1","pages":"387–392"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83762628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 42